OPKO Health Receives Important U.S. Patent Allowance
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE:OPK)
today announced the receipt of a patent allowance from the U.S. Patent
and Trademark Office (USPTO) for the patent titled "Fluidic Connectors
and Microfluidic Systems." These allowed claims cover devices which
enable the reliable long-term storage and eventual delivery of
incompatible reagents on a microfluidic card allowing for the operation
of the system by an untrained user. In addition, the claims encompass a
failsafe mechanism for introduction and pre-treatment of a patient
sample (such as finger-stick blood) into the microfluidic system. This
advancement makes the OPKO point-of-care diagnostic system robust,
stable and easy enough for anyone to use, all of which are critical
differentiating attributes. The technology is well-suited for most
bio-analytical assays such as immunoassays, DNA/RNA detection, general
chemistry and hematology, while it simplifies steps such as filtering,
mixing, and sample preparation as well as washing, amplification, and
detection.
"These particular claims encompass important aspects of reagent storage
and sample collection technology which make our point-of-care system
tremendously easy-to-use," said Phillip Frost, M.D., OPKO Chairman and
CEO. "This technology is applicable to the large menu of tests we have
under development at OPKO."
About OPKO Health, Inc.
OPKO is a multi-national biopharmaceutical and diagnostics company that
seeks to establish industry-leading positions in large and rapidly
growing medical markets by leveraging its discovery, development and
commercialization expertise and novel and proprietary technologies.
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding the potential benefits of OPKO's
point-of-care diagnostic technology, whether a patent for the technology
will issue based on the notice of allowance, our ability to successfully
develop tests utilizing the technology, the ability to differentiate our
product from those of competitors, and the suitability and ease of use
of our product for the point-of care markets, as well as other
non-historical statements about our expectations, beliefs or intentions
regarding our business, technologies and products, financial condition,
strategies or prospects. Many factors could cause our actual activities
or results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include those
described in our filings with the Securities and Exchange Commission,
and risks inherent in funding, developing and obtaining regulatory
approvals of new, commercially-viable and competitive products and
treatments. In addition, forward-looking statements may also be
adversely affected by general market factors, competitive product
development, product availability, federal and state regulations and
legislation, the regulatory process for new products and indications,
manufacturing issues that may arise, patent positions and litigation,
among other factors. The forward-looking statements contained in this
press release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.
OPKO Health, Inc.
Steve Rubin, 305-575-4100
Source: OPKO Health, Inc
News Provided by Acquire Media
Close window | Back to top
